Physician profile
Jack Kim Willis
NPI 1063664183
$1,374.31
in general payments reported to CMS, 2019-2025
24 companies · $679 in 2025
The $679 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.22 · 2022: $258 · 2023: $387 · 2024: $32.67 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,098.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $262.91 | 2022-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $183.01 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $154.73 | 2022-2025 | Ozempic, Rybelsus, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.70 | 2022-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $102.22 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $85.15 | 2023-2025 | |
| Abbott Laboratories | $66.81 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $60.39 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $35.06 | 2022-2025 | |
| Astellas Pharma US INC | $33.16 | 2023 | Veozah, Myrbetriq |
| Genentech USA, INC. | $32.80 | 2021-2022 | |
| Esperion Therapeutics, INC. | $27.75 | 2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.48 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $26.37 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Idorsia Pharmaceuticals US INC | $22.80 | 2023 | Quviviq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $19.87 | 2025 | Inspire |
| Acella Pharmaceuticals, LLC | $19.28 | 2023 | NP Thyroid 60 |
| Merck Sharp & Dohme LLC | $18.01 | 2025 | Gardasil 9, Capvaxive |
| Sanofi-Aventis U.S. LLC | $14.23 | 2022 | |
| Amarin Pharma, INC. | $14.12 | 2022 | |
| Antares Pharma, INC. | $13.53 | 2025 | Xyosted |
| Tris Pharma INC | $13.44 | 2023 | Dyanavel Xr |
| Arbor Pharmaceuticals, INC. | $12.88 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.